Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 19/20 | 0.81 |
| ▸ | CCND1 | P24385 | 19/20 | 0.81 |
| ▸ | CDK6 | Q00534 | 8/20 | 0.81 |
| ▸ | CCND3 | P30281 | 8/20 | 0.81 |
| ▸ | CDK2 | P24941 | 5/20 | 0.81 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.81 |
| ▸ | GAK | O14976 | 1/20 | 0.81 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.81 |
| ▸ | FECH | P22830 | 1/20 | 0.81 |
| ▸ | CDK9 | P50750 | 1/20 | 0.81 |
| ▸ | CDK16 | Q00536 | 1/20 | 0.81 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 0.81 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.81 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.81 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.81 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.81 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.81 |
| ▸ | CDK1 | P06493 | 1/20 | 0.78 |
| ▸ | CCND2 | P30279 | 7/20 | 0.74 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29507453 | 1.00 | CDK4 (0.81) | CDK4CCND1CDK6CCND3CDK2 | |
| Dimethylamine SCHEMBL28726027 | 0.97 | CDK4 (0.80) | CDK4CCND1CDK6CCND3CDK2 | |
| SCHEMBL23837859 | 0.92 | CDK4 (0.83) | CDK4CCND1CDK6CCND3CDK2 | |
| SCHEMBL31121782 | 0.91 | CDK4 (0.80) | CDK4CCND1CDK6CCND3CDK2 | |
| SCHEMBL303542 | 0.91 | CDK4 (0.80) | CDK4CCND1CDK6CCND3CDK2 | |
| SCHEMBL29507623 | 0.91 | CDK4 (0.80) | CDK4CCND1CDK6CCND3CDK2 | |
| SCHEMBL29507498 | 0.90 | CDK4 (0.72) | CDK4CCND1CDK6CCND3CDK2 | |
| SCHEMBL29507471 | 0.90 | CDK4 (0.69) | CDK4CCND1CDK6CCND3CDK2 | |
| Ribociclib SCHEMBL302310 | 0.90 | CDK4 (1.00) | CDK4CCND1CDK6CCND3CDK2 | |
| Ribociclib SCHEMBL29385337 | 0.90 | CDK4 (1.00) | CDK4CCND1CDK6CCND3CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3753933-A1 | SUCCINATE SALT OF 7-CYCLOPENTYL-2 -(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | Novartis AG (CH) | 2020-12-23 | — | — | EP | disclosed |
| EP-2638030-B1 | SUCCINATE SALT OF 7-CYCLOPENTYL-2 -(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | NOVARTIS AG (CH) | 2020-04-15 | — | — | EP | disclosed |
| EP-3279201-B1 | CDK INHIBITOR, EUTECTIC CRYSTAL OF MEK INHIBITOR, AND PREPARATION METHOD THEREFOR | CRYSTAL PHARMATECH CO LTD (CN) | 2019-10-23 | — | — | EP | disclosed |
| EP-3370719-A1 | DOSAGE REGIMEN FOR A PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR | Novartis AG (CH) | 2018-09-12 | — | — | EP | disclosed |
| EP-3279201-A1 | CDK INHIBITOR, EUTECTIC CRYSTAL OF MEK INHIBITOR, AND PREPARATION METHOD THEREFOR | Crystal Pharmatech Co., Ltd. (CN) | 2018-02-07 | — | — | EP | disclosed |
| WO-2017077445-A1 | DOSAGE REGIMEN FOR A PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR | NOVARTIS AG (CH) | 2017-05-11 | — | — | WO | disclosed |
| US-20160039832-A1 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | NOVARTIS AG (CH) | 2016-02-11 | — | — | US | disclosed |
| US-20150099760-A1 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | NOVARTIS AG (CH) | 2015-04-09 | — | — | US | disclosed |
| EP-2331547-B1 | PYRROLOPYRIMIDINE COMPOUNDS AS CDK INHIBITORS | NOVARTIS AG (CH) | 2014-07-30 | — | — | EP | disclosed |
| EP-2638030-A1 | SALT(S) OF 7-CYCLOPENTYL-2 -(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | Novartis AG (CH) | 2013-09-18 | — | — | EP | disclosed |
| US-20130217698-A1 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | ASTEX THERAPEUTICS LTD (GB) | 2013-08-22 | — | — | US | disclosed |
| WO-2012064805-A1 | SALT(S) OF 7-CYCLOPENTYL-2 -(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | NOVARTIS AG (CH) | 2012-05-18 | — | — | WO | disclosed |
| US-20120115878-A1 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | CALIENNI JOHN VINCENT (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150099760-A1 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | PKD2, SLC6A7, DHPS | CDK4 2373/4885CCND1 4058/4885CDK6 1719/4885 |
| US-20160039832-A1 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | PKD2, DHPS, SRM | CDK4 2284/4885CCND1 3904/4885CDK6 1864/4885 |
| US-20130217698-A1 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | PKD2, SLC6A7, DHPS | CDK4 2373/4885CCND1 4058/4885CDK6 1719/4885 |
| US-20120115878-A1 | SALT(S) OF 7-CYCLOPENTYL-2-(5-PIPERAZIN-1-YL-PYRIDIN-2-YLAMINO)-7H-PYRROLO[2,3-D]PYRIMIDINE-6-CARBOXYLIC ACID DIMETHYLAMIDE AND PROCESSES OF MAKING THEREOF | PKD2, SLC6A7, DHPS | CDK4 2373/4885CCND1 4058/4885CDK6 1719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.